Skip to main content
Clinical Trials/NCT03075722
NCT03075722CompletedNot Applicable

The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA): Comfort & Performance Trial

Fisher and Paykel Healthcare2 sites in 1 country14 target enrollmentStarted: March 9, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
14
Locations
2
Primary Endpoint
Draft

Study Overview

Brief Summary

This investigation is designed to evaluate the performance (treatment and leak), comfort (subjective feedback), stability (subjective feedback, leak) as well as the participant's overall acceptance of the Saturn mask amongst OSA participants. An important factor in this investigation will be the testing of our two different seal sizes on the participants (small and medium size). A total number of 15 participants who currently use nasal or nasal pillow masks will be recruited for the trial. A subset of participants have been selected based on their anthropometric measurements collected in previous trials using nasal and nasal pillow masks at this site (CIA-103). Participants from previous NZ trials may be recruited into this trial with their consent. All the participants will be recruited by WellSleep, Wellington.

Participants will use the trial mask in home for a period of 7 ± 3 days. Baseline data will be collected from the participant during the first visit, the prior 7 days of CPAP usage data will be downloaded and stored for our analysis. The participant will use the trial device on their usual CPAP/APAP setting and device for the duration of the trial.

This study will be conducted in accordance with ICH/GCP guidelines. No deviation from the protocol will be implemented without prior review and approval of the sponsor except where it may be necessary to eliminate an immediate hazard to a research participant. In such case, the deviation will be reported to the sponsor as soon as possible.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult (18+ years of age)
  • Able to give consent
  • AHI ≥ 5 on diagnostic night
  • Prescribed a CPAP device after successful OSA diagnosis
  • Existing nasal or nasal pillow mask user

Exclusion Criteria

  • Inability to give consent
  • Participants who are in a coma or a decreased level of consciousness.
  • Anatomical or physiological conditions making APAP therapy inappropriate (e.g. unconsolidated facial structure)
  • Commercial drivers who are investigated by New Zealand Transport Agency (NZTA)
  • Current diagnosis of CO2 retention
  • Pregnant or may think they are pregnant.

Outcomes

Primary Outcomes

Draft

Time Frame: Up to 7 ± 3 days in-home

Subjective questionnaire

Noise

Time Frame: Up to 7 ± 3 days in-home

Subjective questionnaire

Treatment efficacy

Time Frame: Up to 7 ± 3 days in-home

Obtained from participant's CPAP device

Comfort

Time Frame: Up to 7 ± 3 days in-home

Subjective questionnaire

Subjective measurement of leak

Time Frame: Up to 7 ± 3 days in-home

Subjective questionnaire

Objective leak data

Time Frame: Up to 7 ± 3 days in-home

Obtained from participant's CPAP device

Stability

Time Frame: Up to 7 ± 3 days in-home

Subjective questionnaire

Secondary Outcomes

  • Preference of mask(Up to 7 ± 3 days in-home)
  • Usability(Up to 7 ± 3 days in-home)

Investigators

Sponsor
Fisher and Paykel Healthcare
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

The Evaluation of a Nasal Mask for the... | Clinical Trial